ArticleIndian journal of dermatology
Real-World Efficacy and Safety of Ixekizumab in the Treatment of Psoriasis: A Case-Series from Indian Sub-Continent.
Article in Indian journal of dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic, debilitating disease of inflammatory dermatoses. IL-17 plays a pivotal role in the pathogenesis of psoriasis. It acts as a driving force in psoriasis and has a significant role in keratinocyte proliferation, plaque progression, neutrophil recruitment, forming an amplification loop, and formation of tissue-resident memory T helper cells causing relapse. Ixekizumab is a humanized IgG4 monoclonal anti-IL-17 antibody approved for psoriasis in 2016. We are reporting a series of 22 patients presented with moderate to severe psoriasis treated with ixekizumab. 31.8% of patients had pre-existing comorbidities like Hypertension, diabetes, or hypertriglyceridemia. After 14 weeks of treatment, the Mean ± SD PASI improved from 30.82 ± 7.06 to 2.82 ± 3.12. At the end of treatment (14
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.